Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus

被引:89
|
作者
Bakris, George L. [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; BLOOD-PRESSURE CONTROL; ALL-CAUSE MORTALITY; RENAL-FUNCTION; MULTIFACTORIAL INTERVENTION; FOLLOW-UP; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE;
D O I
10.4065/mcp.2010.0713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nephropathy Is a common microvascular complication among patients with type 2 diabetes mellitus and a major cause of kidney failure. It is characterized by albuminuria (>= 300 mg/d) and a reduced glomerular filtration rate and is often present at the time of diabetes diagnosis after the kidney has been exposed to chronic hyperglycemia during the prediabetic phase. A low glomerular filtration rate (< 60 mL/min/1.73 m(2)) is also an independent risk factor for cardiovascular events and death. Detection of diabetic nephropathy during its initial stages provides the opportunity for early therapeutic interventions to prevent or delay the onset of complications and improve outcomes. An intensive and multifactorial management approach is needed that targets all risk determinants simultaneously. The strategy should comprise lifestyle modifications (smoking cessation, weight loss, increased physical activity, and dietary changes) coupled with therapeutic achievement of blood glucose, blood pressure, and lipid goals that are evidence-based. Prescribing decisions should take into account demographic factors, level of kidney impairment, adverse effects, risk of hypoglycemia, tolerability, and effects on other risk factors and comorbidities. Regular and comprehensive follow-up assessments with appropriate adjustment of the therapeutic regimen to maintain risk factor control is a vital component of care, including referral to specialists, when required.
引用
收藏
页码:444 / 456
页数:13
相关论文
共 50 条
  • [1] Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus
    Wanner, Christoph
    Krane, Vera
    KIDNEY & BLOOD PRESSURE RESEARCH, 2011, 34 (04) : 209 - 217
  • [2] Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study
    Hu, Yuhong
    Shi, Rong
    Mo, Ruohui
    Hu, Fan
    AGING-US, 2020, 12 (11): : 10317 - 10336
  • [3] Nephropathy Following Type 2 Diabetes Mellitus in Tunisian Population
    Bouaziz, A.
    Zidi, I.
    Zidi, N.
    Mnif, W.
    Zinelabidine, H. T.
    WEST INDIAN MEDICAL JOURNAL, 2012, 61 (09) : 881 - 889
  • [4] Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy
    Hanai, Ko
    Babazono, Tetsuya
    Nyumura, Izumi
    Toya, Kiwako
    Ohta, Mari
    Bouchi, Ryotaro
    Suzuki, Kumi
    Inoue, Aiko
    Iwamoto, Yasuhiko
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2010, 14 (02) : 132 - 136
  • [5] Development of a fuzzy expert system for the nephropathy control assessment in patients with type 2 diabetes mellitus
    Meza-Palacios, Ramiro
    Aguilar-Lasserre, Alberto A.
    Urena-Bogarin, Enrique L.
    Vazquez-Rodriguez, Carlos F.
    Posada-Gomez, Ruben
    Trujillo-Mata, Armin
    EXPERT SYSTEMS WITH APPLICATIONS, 2017, 72 : 335 - 343
  • [6] Adiponectin gene polymorphisms in Egyptian type 2 diabetes mellitus patients with and without diabetic nephropathy
    El-Shal, Amal S.
    Zidan, Haidy E.
    Rashad, Nearmeen M.
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (04) : 2287 - 2298
  • [7] Treatment of type 2 diabetes mellitus in elderly patients
    Gomez-Huelgas, R.
    Gomez Peralta, F.
    Rodriguez Manas, L.
    Formiga, F.
    Puig Domingo, M.
    Mediavilla Bravo, J. J.
    Miranda, C.
    Ena, J.
    REVISTA CLINICA ESPANOLA, 2018, 218 (02): : 74 - 88
  • [8] The Impact of Hypoxemia on Nephropathy in Extremely Obese Patients with Type 2 Diabetes Mellitus
    Leong, Wen Bun
    Nolen, Melissa
    Thomas, G. Neil
    Adab, Paymane
    Banerjee, Dev
    Taheri, Shahrad
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2014, 10 (07): : 773 - 778
  • [9] Cystatin C as an Early Biomarker of Nephropathy in Patients with Type 2 Diabetes
    Jeon, Yun Kyung
    Kim, Mi Ra
    Huh, Jung Eun
    Mok, Ji Young
    Song, Sang Heon
    Kim, Sang Soo
    Kim, Bo Hyun
    Lee, Soo Hyoung
    Kim, Yong Ki
    Kim, In Joo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (02) : 258 - 263
  • [10] Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus
    Guo, Xinyang
    Xing, Yiqiao
    Jin, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14